%0 Journal Article
%A Piñana, José Luis
%A López-Corral, Lucia
%A Martino, Rodrigo
%A Montoro, Juan
%A Vazquez, Lourdes
%A Pérez, Ariadna
%A Martin-Martin, Gabriel
%A Facal-Malvar, Ana
%A Ferrer, Elena
%A Pascual, María-Jesús
%A Sanz-Linares, Gabriela
%A Gago, Beatriz
%A Sanchez-Salinas, Andrés
%A Villalon, Lucia
%A Conesa-Garcia, Venancio
%A Olave, Maria T
%A López-Jimenez, Javier
%A Marcos-Corrales, Sara
%A García-Blázquez, Marta
%A Garcia-Gutiérrez, Valentín
%A Hernández-Rivas, José Ángel
%A Saus, Ana
%A Espigado, Ildefonso
%A Alonso, Carmen
%A Hernani, Rafael
%A Solano, Carlos
%A Ferrer-Lores, Blanca
%A Guerreiro, Manuel
%A Ruiz-García, Montserrat
%A Muñoz-Bellido, Juan Luis
%A Navarro, David
%A Cedillo, Angel
%A Sureda, Anna
%A Infectious Complications Subcommittee of the Spanish Hematopoietic Stem Cell Transplantation and Cell Therapy Group (GETH-TC)
%T SARS-CoV-2-reactive antibody detection after SARS-CoV-2 vaccination in hematopoietic stem cell transplant recipients: Prospective survey from the Spanish Hematopoietic Stem Cell Transplantation and Cell Therapy Group.
%D 2021
%U http://hdl.handle.net/10668/19952
%X This is a multicenter prospective observational study that included a large cohort (n = 397) of allogeneic (allo-HSCT; (n = 311) and autologous (ASCT) hematopoietic stem cell transplant (n = 86) recipients who were monitored for antibody detection within 3-6 weeks after complete severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination from February 1, 2021, to July 20, 2021. Most patients (n = 387, 97.4%) received mRNA-based vaccines. Most of the recipients (93%) were vaccinated more than 1 year after transplant. Detectable SARS-CoV-2-reactive antibodies were observed in 242 (78%) of allo-HSCT and in 73 (85%) of ASCT recipients. Multivariate analysis in allo-HSCT recipients identified lymphopenia
%~